Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors-Reference-Cited by-同舟云学术

Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors

Published:2015-02-03 Issue:11 Volume:121 Page:1817-1826
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Abu-Khalaf Maysa M.¹,Baumgart Megan A.²,Gettinger Scott N.¹,Doddamane Indukala³,Tuck David P.⁴,Hou Shihe⁵,Chen Nianhang⁵,Sullivan Catherine¹,Lezon-Geyda Kimberly¹,Zelterman Daniel⁶,Hatzis Christos¹,Deshpande Hari¹,Digiovanna Michael P.¹,Azodi Masoud⁷,Schwartz Peter E.⁷,Harris Lyndsay N.⁸

Affiliation:

1. Department of Medical Oncology; Yale University School of Medicine; New Haven Connecticut

2. Department of Medical Oncology; University of Rochester; Rochester New York

3. Department of Diagnostic Imaging; Yale University School of Medicine; New Haven Connecticut

4. EMD Serono; Billerica Massachusetts

5. Celgene Corporation; Berkeley Heights New Jersey

6. Department of Epidemiology and Public Health; Yale University School of Medicine; New Haven Connecticut

7. Department of Gynecologic Oncology; Yale University School of Medicine; New Haven Connecticut

8. Department of Medical Oncology; Case Western University; Cleveland Ohio

Funder

Susan G. Komen for the Cure

Celgene

Breast Cancer Alliance

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.29254/fullpdf

Reference32 articles.

1. Current development of mTOR inhibitors as anticancer agents;Faivre;Nat Rev Drug Discov,2006

2. Targeting the molecular target of rapamycin (mTOR);Rowinsky;Curr Opin Oncol,2004

3. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer;Chan;Br J Cancer,2004

4. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression;Fingar;Oncogene,2004

5. Sirolimus for the prevention of in-stent restenosis in a coronary artery;Marks;N Engl J Med,2003

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in nanomaterials for the diagnosis and treatment of head and neck cancers: A review;Bioactive Materials;2023-07

2. Pharmacological impact of microRNAs in head and neck squamous cell carcinoma: Prevailing insights on molecular pathways, diagnosis, and nanomedicine treatment;Frontiers in Pharmacology;2023-05-03

3. Nanomedicine for autophagy modulation in cancer therapy: a clinical perspective;Cell & Bioscience;2023-03-04

4. Albumin Binds Doxorubicin via Self–Assembling Dyes as Specific Polymolecular Ligands;International Journal of Molecular Sciences;2022-05-01

5. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside;Seminars in Cancer Biology;2019-12